Ezetimibe : NICE guidance

The management of hypercholesterolaemia often involves a multi-faceted approach that includes lifestyle modification, dietary counselling, and pharmacotherapy. Statins have long been the cornerstone of lipid-lowering therapy. However, there are instances where statins may not be appropriate or tolerated by the patient. Ezetimibe offers an alternative or complementary mode of cholesterol reduction. The National Institute for Health and Care Excellence (NICE) provides comprehensive guidance on when and how to utilize Ezetimibe in clinical practice.

The following table synthesizes key points from the NICE guidelines on the use of Ezetimibe, either as monotherapy or in combination with statins. This condensed information is aimed at aiding clinicians in making evidence-based decisions for managing patients with primary hypercholesterolaemia, be it heterozygous-familial or non-familial.

Recommendation	Rationale	Additional Information
Ezetimibe monotherapy is an option for adults who cannot tolerate statins.	Suitable for those with clinically significant adverse effects from statins.	Intolerance to statins is defined as clinically significant adverse effects.
Co-administer ezetimibe with initial statin therapy if LDL-C or total cholesterol is not well controlled.	Enhances lipid-lowering effects when statin alone is insufficient or when dose titration of initial statin is limited by intolerance.	Consider changing statin if not controlled.
When co-prescribed with a statin, choose...

Try our Free Plan to get the full article.